|
|
|
| Research progress of epidermal growth factor receptor targeted therapy for cervical cancer |
| HAN Buwei1 LIU Yang1 LIU Ning1 HAO Xinying1 ZHOU Lina1 QI Ding1 YUAN Mengke1 LIU Li2 |
1.Graduate School, Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China;
2.Ward Two， Department of Gynecology, the First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China
|
|
|
|
Abstract The occurrence of cervical cancer is generally associated with human papillomavirus (HPV) infection, and there was a strong correlation between HPV infection and epidermal growth factor receptor (EGFR) signaling cascade upregulation. Therefore, EGFR is commonly targeted and used to treat cervical cancer using tyrosine kinase inhibitors and monoclonal antibodies. This review aims to integrate contemporary approaches to EGFR-targeted therapy of cervical cancer and highlight the current differential roles of microRNA and associated genes in cervical cancer involving EGFR mutations. Potential resistance to existing EGFR therapies and the need for better therapies are reviewed and discussed with a view to developing novel agents with better efficacy.
|
|
|
|
|
|
[1] Arbyn M，Gultekin M，Morice P，et al. The European response to the WHO call to eliminate cervical cancer as a public health problem [J]. Int J Cancer，2021，148（2）：277-284.
[2] 张婷婷，刘宝财，卢银亮，等.缺氧对乳腺癌和宫颈癌裸鼠移植瘤EGFR表达及细胞凋亡的影响[J].中华放射肿瘤学杂志，2019，28（6）：442-444.
[3] Valle-Mendiola A，Bustos-Rodríguez R，Domínguez-Melendez V，et al. Mutations in the helix αC of the catalytic domain from the EGFR affect its activity in cervical cancer cell lines [J]. Oncol Lett，2022，23（2）：71.
[4] Morgan EL，Scarth JA，Patterson MR，et al. E6-mediated activation of JNK drives EGFR signalling to promote proliferation and viral oncoprotein expression in cervical cancer [J]. Cell Death Differ，2021，28（5）：1669-1687.
[5] Schrevel M，Osse EM，Prins FA，et al. Autocrine expression of the epidermal growth factor receptor ligand heparin-binding EGF-like growth factor in cervical cancer [J]. Int J Oncol，2017，50（6）：1947-1954.
[6] 向花花，周晶，彭华，等.基因G719S和T790M突变与宫颈癌的相关性研究[J].中华医学遗传学杂志，2019，36（4）：376-379.
[7] Yadav SK，Verma A，Sarin N，et al. Expression of epidermal growth factor receptor in squamous cell carcinoma of uterine cervix [J]. Clin Cancer Investig J，2019，8：227-231.
[8] 裴峰，罗倩，吕文静.Hippo/YAP信号通路对HPV感染宫颈癌细胞调节作用[J].中华肿瘤防治杂志，2019，26（3）：148-154.
[9] Babion I，Miok V，Jaspers A，et al. Identification of Deregulated Pathways，Key Regulators，and Novel miRNA-mRNA Interactions in HPV-Mediated Transformation [J]. Cancers （Basel），2020，12（3）：700.
[10] Norouzi S，Farhadi A，Farzadfard E，et al. MicroRNAs Expression Changes Coincide with Low or High Grade of Squamous Intraepithelial Lesion Infected by HPV-16 [J]. Gene Rep，2021，23：101186.
[11] Zhao S，Xie J，Zhao C，et al. Ultrasound-Targeted Microbubble Destruction Enhances the Inhibitive Efficacy of miR-21 Silencing in HeLa Cells [J]. Med Sci Monit，2021， 27：e923660.
[12] Poltronieri P，Sun B，Huang KY，et al. State-of-the-Art on Viral microRNAs in HPV Infection and Cancer Development [J]. Microrna，2018，7（2）：85-91.
[13] Cao Q，Wang N，Ren L，et al. miR-125a-5p post-transcriptionally suppresses GALNT7 to inhibit proliferation and invasion in cervical cancer cells via the EGFR/ PI3K/AKT pathway [J]. Cancer Cell Int，2020，20：117.
[14] Komatsu M，Nakamura K，Takeda T，et al. Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signalling [J]. Oncogene，2022，41（16）：2326-2339.
[15] Zheng J，Yu J，Yang M，et al. Gefitinib suppresses cervical cancer progression by inhibiting cell cycle progression and epithelial-mesenchymal transition [J]. Exp Ther Med，2019，18（3）：1823-1830.
[16] Zhou L，Zhang H，Huang C，et al. Expression of Daxx and HPV16 E6 and its significance in cervical lesions [J]. Chin Med J，2015，95（37）：3050-3053.
[17] Wei H，Wang XW，Chen KM，et al. Analysis of gene mutation associated with tyrosine kinase inhibitor sensitivity of epidermal growth factor receptor in cervical cancer patients [J]. Eur Rev Med Pharmacol Sci，2018，22（19）：6280-6287.
[18] Qureshi R，Arora H，Biswas S，et al. Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients [J]. Tumour Biol，2016，37（7）：9089-9098.
[19] Benson R，Pathy S，Kumar L，et al. Locally advanced cervical cancer-neoadjuvant chemotherapy followed by concurrent chemoradiation and targeted therapy as maintenance：A phase Ⅱ study [J]. J Cancer Res Ther，2019，15（6）：1359- 1364.
[20] Schilder RJ，Sill MW，Lee YC，et al. A phase Ⅱ trial of erlotinib in recurrent squamous cell carcinoma of the cervix：a Gynecologic Oncology Group Study [J]. Int J Gynecol Cancer，2009，19（5）：929-933.
[21] Callegaro-Filho D，Kavanagh JJ，Nick AM，et al. Sustained complete response after maintenance therapy with topotecan and erlotinib for recurrent cervical cancer with distant metastases [J]. Case Rep Oncol，2014，7（1）：97-101.
[22] Nogueira-Rodrigues A，do Carmo CC，Viegas C，et al. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer [J]. Clin Cancer Res，2008，14（19）：6324- 6329.
[23] Li F，Mei H，Xie X，et al. Aptamer-Conjugated Chitosan- Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells [J]. AAPS J，2017，19（3）：814-826.
[24] Birle DC，Hedley DW. Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts [J]. Mol Cancer Ther，2006，5（10）：2494-2502.
[25] Chen X，Xu P，Zhang H，et al. EGFR and ERK activation resists flavonoid quercetin-induced anticancer activities in human cervical cancer cells in vitro [J]. Oncol Lett，2021，22（5）：754.
[26] Ha GH，Park JS，Breuer EK. TACC3 promotes epithelial- mesenchymal transition （EMT） through the activation of PI3K/Akt and ERK signaling pathways [J]. Cancer Lett，2013，332（1）：63-73.
[27] Schmid S，Li JJN，Leighl NB. Mechanisms of osimertinib resistance and emerging treatment options [J]. Lung Cancer，2020，147：123-129.
[28] Bellati F，Napoletano C，Gasparri ML，et al. Monoclonal antibodies in gynecological cancer：a critical point of view [J]. Clin Dev Immunol，2011，2011：890758.
[29] Voigt M，Braig F，G?觟thel M，et al. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab [J]. Neoplasia，2012，14（11）：1023-1031.
[30] Li C，Iida M，Dunn EF，et al. Nuclear EGFR contributes to acquired resistance to cetuximab [J]. Oncogene，2009，28（43）：3801-3813. |
|
|
|
